{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:51:08Z","timestamp":1773525068075,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\"Proyectos L\u00edneas Estrat\u00e9gicas Colaboraci\u00f3n\" funded by the Ministerio de Inovaci\u00f3n y Ciencias and the \"Uni\u00f3n Europea Next Generation\"","award":["PLEC2021-007892"],"award-info":[{"award-number":["PLEC2021-007892"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["DTS21\/00111"],"award-info":[{"award-number":["DTS21\/00111"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI 18\/01408"],"award-info":[{"award-number":["PI 18\/01408"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the  \"Proyectos L\u00edneas Estrat\u00e9gicas Colaboraci\u00f3n\" funded by the Ministerio de Inovaci\u00f3n y Ciencias and the \"Uni\u00f3n Europea Next Generation\"","award":["PLEC2021-007892"],"award-info":[{"award-number":["PLEC2021-007892"]}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n FERO","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funding from the first edition of the mama's chukker charity polo match held in Madrid in 2023"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10549-026-07931-7","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:11:46Z","timestamp":1772269906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world second- and third-line progression-free survival after progression on first-line CDK4\/6 inhibitors in HR+\/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study"],"prefix":"10.1007","volume":"216","author":[{"given":"Pablo","family":"Tolosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Garc\u00eda-Fructuoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Miguel","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier David","family":"Benitez Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Parrilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla Alicia","family":"Centelles L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"S\u00e1nchez-Bayona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"S\u00e1nchez-Belmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Malumbres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"7931_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"7931_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"7931_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"7931_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541\u20131547. https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"key":"7931_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386:942\u2013950. https:\/\/doi.org\/10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"key":"7931_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andr\u00e9","year":"2021","unstructured":"Andr\u00e9 F, Ciruelos EM, Juric D et al (2021) Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 32:208\u2013217. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011","journal-title":"Ann Oncol"},{"key":"7931_CR7","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ et al (2023) Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388:2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","journal-title":"N Engl J Med"},{"key":"7931_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer. N Engl J Med 366:520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"7931_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-024-07324-8","volume":"206","author":"R Sanchez-Bayona","year":"2024","unstructured":"Sanchez-Bayona R, Lopez de Sa A, Jerez Gilarranz Y et al (2024) Everolimus plus endocrine therapy beyond CDK4\/6 inhibitors progression for HR+ \/HER2- advanced breast cancer: a real-world evidence cohort. Breast Cancer Res Treat 206:551\u2013559. https:\/\/doi.org\/10.1007\/s10549-024-07324-8","journal-title":"Breast Cancer Res Treat"},{"key":"7931_CR10","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Kaklamani VG, Neven P et al (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40:3246\u20133256. https:\/\/doi.org\/10.1200\/JCO.22.00338","journal-title":"J Clin Oncol"},{"key":"7931_CR11","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C et al (2023) Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: Maintain trial. J Clin Oncol 41:4004\u20134013. https:\/\/doi.org\/10.1200\/JCO.22.02392","journal-title":"J Clin Oncol"},{"key":"7931_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E et al (2025) Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol 43:1101\u20131112. https:\/\/doi.org\/10.1200\/JCO-24-02086","journal-title":"J Clin Oncol"},{"key":"7931_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML et al (2025) Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 392:1189\u20131202. https:\/\/doi.org\/10.1056\/NEJMoa2410858","journal-title":"N Engl J Med"},{"key":"7931_CR14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","volume":"39","author":"A Prat","year":"2021","unstructured":"Prat A, Chaudhury A, Solovieff N et al (2021) Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol 39:1458\u20131467. https:\/\/doi.org\/10.1200\/JCO.20.02977","journal-title":"J Clin Oncol"},{"key":"7931_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0561","author":"A Prat","year":"2023","unstructured":"Prat A, Solovieff N, Andre F et al (2023) Intrinsic subtype and overall survival of patients with advanced HR+\/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0561","journal-title":"Clin Cancer Res"},{"key":"7931_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115219","author":"P Tolosa","year":"2025","unstructured":"Tolosa P, Pascual T, Mart\u00ednez-Saez O et al (2025) Efficacy outcomes of CDK4\/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive\/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801 CDK-PREDICT study. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2024.115219","journal-title":"Eur J Cancer"},{"key":"7931_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1634\/theoncologist.2018-0407","volume":"24","author":"A Prat","year":"2019","unstructured":"Prat A, Brase JC, Cheng Y et al (2019) Everolimus plus exemestane for hormone receptor-positive advanced breast cancer: a PAM50 intrinsic subtype analysis of BOLERO-2. Oncologist 24:893\u2013900. https:\/\/doi.org\/10.1634\/theoncologist.2018-0407","journal-title":"Oncologist"},{"key":"7931_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-22-2206","volume":"29","author":"\u00c1 Guerrero-Zotano","year":"2023","unstructured":"Guerrero-Zotano \u00c1, Belli S, Zielinski C et al (2023) CCNE1 and PLK1 mediate resistance to palbociclib in HR+\/HER2- metastatic breast cancer. Clin Cancer Res 29:1557\u20131568. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2206","journal-title":"Clin Cancer Res"},{"key":"7931_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00297-1","volume":"6","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Turner NC, Loi S et al (2022) Comparative biomarker analysis of PALOMA-2\/3 trials for palbociclib. NPJ Precis Oncol 6:56. https:\/\/doi.org\/10.1038\/s41698-022-00297-1","journal-title":"NPJ Precis Oncol"},{"key":"7931_CR20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast\u00a0cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"7931_CR21","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS2-07","volume":"31","author":"I Garcia-Fructuoso","year":"2025","unstructured":"Garcia-Fructuoso I, Bras\u00f3-Maristany F, Mart\u00ednez-S\u00e1ez O et al (2025) Abstract PS2-07: intrinsic subtype at progression to CDK4\/6 inhibitors plus endocrine therapy in hormone receptor-positive\/HER2-negative metastatic breast cancer (MBC). Clin Cancer Res 31:PS2-07. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-PS2-07","journal-title":"Clin Cancer Res"},{"key":"7931_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/oncolo\/oyac075","volume":"27","author":"JM Martin","year":"2022","unstructured":"Martin JM, Handorf EA, Montero AJ, Goldstein LJ (2022) Systemic therapies following progression on first-line CDK4\/6-inhibitor treatment: analysis of real-world data. Oncologist 27:441\u2013446. https:\/\/doi.org\/10.1093\/oncolo\/oyac075","journal-title":"Oncologist"},{"key":"7931_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12269-8","volume":"24","author":"V Lambert","year":"2024","unstructured":"Lambert V, Kane S, Howidi B et al (2024) Systematic literature review of real-world evidence for treatments in HR+\/HER2- second-line LABC\/mBC after first-line treatment with CDK4\/6i. BMC Cancer 24:631. https:\/\/doi.org\/10.1186\/s12885-024-12269-8","journal-title":"BMC Cancer"},{"key":"7931_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/oncolo\/oyad035","volume":"28","author":"MT West","year":"2023","unstructured":"West MT, Goodyear SM, Hobbs EA et al (2023) Real-world evaluation of disease progression after CDK 4\/6 inhibitor therapy in patients with hormone receptor-positive metastatic breast cancer. Oncologist 28:682\u2013690. https:\/\/doi.org\/10.1093\/oncolo\/oyad035","journal-title":"Oncologist"},{"key":"7931_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105808","volume":"10","author":"LFC de Almeida","year":"2025","unstructured":"de Almeida LFC, Leite LF, Filho VOC et al (2025) Cyclin-dependent kinase 4\/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study). ESMO Open 10:105808. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105808","journal-title":"ESMO Open"},{"key":"7931_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K et al (2025) Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2505725","journal-title":"N Engl J Med"},{"key":"7931_CR27","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E et al (2024) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 25:e629\u2013e638. https:\/\/doi.org\/10.1016\/S1470-2045(24)00673-9","journal-title":"Lancet Oncol"},{"key":"7931_CR28","unstructured":"Mayer E., et al (2025) Primary results of the phase III evERA BC trial: Giredestrant + everolimus in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4\/6 inhibitor. ESMO Congress 2025, Berlin, Germany, 17\u201321 Oct 2025. Abstract LBA16."},{"key":"7931_CR29","unstructured":"Hurvitz S., et al (2025) VIKTORIA-1: A phase III study of Gedatolisib combination therapy in HR+\/HER2\u2013 advanced breast cancer post-CDK4\/6 inhibitor. ESMO Congress 2025, Berlin, Germany, 17\u201321 Oct 2025. (Late-breaker abstract)."},{"key":"7931_CR30","doi-asserted-by":"publisher","unstructured":"Updated efficacy of mutant-selective PI3K\u03b1 inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced breast cancer (2025) ReDiscover trial. | Journal of Clinical Oncology. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1086. Accessed 22 Jul 2025","DOI":"10.1200\/JCO.2025.43.16_suppl.1086"},{"key":"7931_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 402:1423\u20131433. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X","journal-title":"Lancet"},{"key":"7931_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"7931_CR33","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"7931_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13059","volume":"42","author":"E Kim","year":"2024","unstructured":"Kim E, Dhillon PK, Lambert P et al (2024) PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice. JCO 42:e13059\u2013e13059. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e13059","journal-title":"JCO"},{"key":"7931_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3759179","volume":"2020","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Mollon LE, Dean JL et al (2020) A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+\/HER2\u2013 metastatic breast cancer. Int J Breast Cancer 2020:3759179. https:\/\/doi.org\/10.1155\/2020\/3759179","journal-title":"Int J Breast Cancer"},{"key":"7931_CR36","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1200\/JCO.20.02272","volume":"39","author":"A Bardia","year":"2021","unstructured":"Bardia A, Kaklamani V, Wilks S et al (2021) Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. JCO 39:1360\u20131370. https:\/\/doi.org\/10.1200\/JCO.20.02272","journal-title":"JCO"},{"key":"7931_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55914-x","volume":"16","author":"Z Kan","year":"2025","unstructured":"Kan Z, Wen J, Bonato V et al (2025) Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors. Nat Commun 16:932. https:\/\/doi.org\/10.1038\/s41467-025-55914-x","journal-title":"Nat Commun"},{"key":"7931_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00925","author":"NC Turner","year":"2019","unstructured":"Turner NC, Liu Y, Zhu Z et al (2019) Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor\u2013positive metastatic breast cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.18.00925","journal-title":"J Clin Oncol"},{"key":"7931_CR39","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41416-023-02451-3","volume":"129","author":"S Makhlouf","year":"2023","unstructured":"Makhlouf S, Wahab N, Toss M et al (2023) Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence. Br J Cancer 129:1747\u20131758. https:\/\/doi.org\/10.1038\/s41416-023-02451-3","journal-title":"Br J Cancer"},{"key":"7931_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.07.005","author":"YA Civil","year":"2025","unstructured":"Civil YA, Purcell ND, de Vries R et al (2025) Prognostic value of tumor-infiltrating lymphocytes in breast cancer patients treated with radiotherapy: a systematic review of literature. Clin Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2025.07.005","journal-title":"Clin Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07931-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:02:20Z","timestamp":1773522140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07931-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7931"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07931-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.T. reports advisory and consulting fees from AstraZeneca, Daiichi Sankyo, Adamed, Novartis, Pfizer, Lilly, Esteve, Gilead, Roche, and Reveal Genomics. I.G-F. reports invited speaker fees from Novartis, Daiichi Sankyo, and Eisai; advisory\/consulting fees from Novartis; and travel expenses from Novartis, Gilead, and Lilly. T.P. reports advisory and consulting fees or speaker honoraria from Novartis, AstraZeneca, Lilly, Pfizer, Veracyte, Gilead, and Roche, and support for attending meetings and\/or travel from Gilead. O.M-S. reports advisory\/consulting fees from Reveal Genomics, Roche, and AstraZeneca; lecture fees from Daiichi Sankyo, Novartis, Pfizer, and Eisai; and travel expenses from Gilead and Novartis. E.S. reports participation in advisory boards and as a speaker for AstraZeneca and Sysmex, and consultancy for Reveal Genomics Inc. F.B-M. reports patents filed (PCT\/EP2022\/086493, PCT\/EP2023\/060810, EP23382703, and EP23383369) and part-time employment by Reveal Genomics. R.S-B. reports advisory\/consulting\/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, Eisai, GlaxoSmithKline, Reveal Genomics, and Gilead; and travel expenses from Pfizer, AstraZeneca, Gilead, Novartis, and Roche. A.M. reports honoraria from AstraZeneca, Clovis, GSK, PharmaMar, Immunogen, and Pharma&. F.S. has been employed by AstraZeneca since June 2024; however, involvement in this study predates this employment, and AstraZeneca had no involvement in the study. M.M. reports advisory\/consulting\/speaker fees or grant support from AstraZeneca, PharmEnable, PharmaMar, and Circle Pharma. A.P. reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc; lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo; institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; and patents filed (PCT\/EP2016\/080056, PCT\/EP2022\/086493, PCT\/EP2023\/060810, EP23382703, and EP23383369). E.C. reports advisory\/consulting\/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, and Gilead; and travel expenses from Pfizer, AstraZeneca, MSD, Novartis, and Roche. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"21"}}